Anavex Life Sciences Corp (AVXL)

[JKS3]

Ladies and gentlemen, this is roughly the percentage of patients defined by the primary endpoints. All values are approximate. This is my calculation based on the distribution and regression.

ADAS-COG: for the control arm, there are roughly 28% of patients remain “improved” (-0.5); roughly 51% in the treatment arm (273) remain "improved).
ADCS-ADL: for the control arm, there are roughly 6% of patients remain “improved” (3.5); roughly 16% of patients in the treatment arm remain improved.